Enteric fever in an under 5-year-old.

S. Ahmad,S. M. Ali,P. Ahmad

DOI: https://doi.org/10.1093/tropej/37.2.91

1991-04-01

Journal of Tropical Pediatrics

Abstract:

What problem does this paper attempt to address?

Real-world Experience of Nintedanib Therapy in Idiopathic-inflammatory-myopathy-related Interstitial Lung Disease: Efficacy and Tolerability

Junyu Liang,H. Cao,Yang,Y. Ke,Chuanyin Sun,L. Yue,Jin Lin

DOI: https://doi.org/10.21203/rs.3.rs-52262/v1

2020-01-01

Abstract:BackgroundInterstitial lung disease (ILD) is a common and frequently fatal extra-muscular complication in patients with idiopathic inflammatory myopathy (IIM), and is refractory to the conventional immunosuppressive medications. Nintedanib has previously been proven to be effective and tolerable in idiopathic pulmonary fibrosis, systemic-sclerosis-related ILD, etc. However, the efficacy and safety of nintedanib in idiopathic-inflammatory-myopathy-related ILD (IIM-ILD) remain unknown. The purpose of this study was to initially explore the efficacy and tolerability of nintedanib in IIM-ILD patients.MethodsA real-world analysis was conducted to explore the efficacy and tolerability of nintedanib in IIM-ILD patients who regularly received outpatient visit or hospitalization from January 2018 to October 2019 in one medical center. The primary end point was occurrence of rapid progression of interstitial lung disease (RP-ILD) in the follow-up. And time to death from any cause, complication of pulmonary infection and difference in immunosuppressive regimen were taken as secondary end points in this study. Adverse events were descriptively recorded.Results22 patients receiving nintedanib therapy and 82 patients under conventional medications were included. After propensity score matching, the primary comparison revealed that better survival (P = 0.036) and prominently less RP-ILD (P = 0.031) in patients with nintedanib therapy. Logistic regression analysis identified that disease activity (P = 0.032), anti-PM-Scl75 antibody (P = 0.027) and nintedanib therapy (P = 0.023, OR value = 0.063) were significantly correlated with RP-ILD. Cox proportional hazards regression analysis demonstrated that disease activity (P = 0.007), anti-MDA5 antibody (P = 0.004) and nintedanib therapy (P = 0.027, HR value = 0.190) were significantly associated with survival of IIM-ILD patients. Similar results can also be seen in analyses before propensity score matching. In the 22 patients with nintedanib therapy, diarrhea was the most common adverse event (54.5%) and hepatic insufficiency contributed to most dosage reduction (50%) or therapy discontinuation (50%).ConclusionNintedanib therapy might reduce incidence of RP-ILD and improve survival in IIM-ILD patients. Anti-PM-Scl75 and anti-MDA5 antibodies could predict RP-ILD and survival respectively. In addition to the most frequent diarrhea, hepatic insufficiency was closely related to dosage reduction or therapy discontinuation.Trial registration:ISRCTN.com, ISRCTN 10507540. Retrospectively registered.
The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis

Vincent Cottin

DOI: https://doi.org/10.1080/14740338.2017.1338268

2017-06-15

Expert Opinion on Drug Safety

Abstract:INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease that primarily affects older individuals. Nintedanib, a tyrosine kinase inhibitor, has been approved for the treatment of IPF in several countries. The safety and tolerability of nintedanib have been investigated in clinical trials and in real-world studies (compassionate use programs and post-marketing surveillance). Areas covered: Most frequent adverse events reported in patients treated with nintedanib (gastrointestinal); additional adverse events of special interest (elevations in liver enzymes, bleeding, cardiovascular adverse events); recommendations for managing adverse events. Expert opinion: Experience with nintedanib in real-world clinical practice suggests that it has a safety and tolerability profile consistent with that observed in clinical trials. Upon initiation of nintedanib, patient education, regular monitoring and proactive management of adverse events such as diarrhea are needed to minimize the risk of permanent treatment discontinuation. Algorithms are available to help manage diarrhea and liver enzyme elevations. Further investigation of the safety and tolerability profile of nintedanib when used in combination with pirfenidone is warranted.

pharmacology & pharmacy
Succinic thiokinase. IV. Improved method of purification, arsenolysis of guanosine triphosphate, succinate-dependent guanosine triphos- phatase activity, and some other properties of the enzyme.

S. Cha,C. Cha,R. Parks

IF: 5.485

1967-06-10

Journal of Biological Chemistry

Abstract:Abstract A method of purification of succinic thiokinase from pig hearts is described by which a 700- to 800-fold purification over the crude extract may be achieved with about 10% recovery. The final product has a specific activity of about 110 µm units per mg, and the molecular weight of the enzyme is estimated as about 70,000. The stability of the enzyme at various pH values is presented. Two previously unobserved reactions catalyzed by the enzyme are described. The relative rates of catalysis of the normal reaction, the coenzyme A-dependent arsenolysis of guanosine triphosphate, and the succinate-dependent guanosine triphosphatase are approximately 1, 0.008, and 0.0004 respectively. Substrate activities of 6-thioguanosine triphosphate and dephospho-coenzyme A are described.
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Eva Brunnemer,Julia Wälscher,Svenja Tenenbaum,Julia Hausmanns,Karen Schulze,Marianne Seiter,Claus Peter Heussel,Arne Warth,Felix J.F. Herth,Michael Kreuter,Claus Peter Heussel,Felix J.F. Herth

DOI: https://doi.org/10.1159/000485933

2018-01-01

Respiration

Abstract:BACKGROUND: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, real-world experience is limited.OBJECTIVE: To assess the efficacy and safety of nintedanib in a large cohort of patients treated at a tertiary referral site for interstitial lung diseases.METHODS: The records of patients with a confirmed diagnosis of IPF were reviewed. Full medical history, pulmonary function, and adverse events (AEs) were recorded from each clinic visit. Disease progression was defined as a reduction in FVC ≥5% and/or in diffusing capacity of the lung for carbon monoxide ≥15% according to recent publications. Only patients with a treatment duration ≥3 months were included in the efficacy evaluation.RESULTS: A total of 64 patients were treated. Mean ± standard deviation (SD) FVC was 71 ± 21% predicted, and the mean time from diagnosis to initiation of nintedanib treatment was 23.8 months. Nearly half of patients (n = 30, 47%) had received prior pirfenidone treatment. The mean duration of follow-up was 11 months. At 6 months following initiation of nintedanib, 67% of the patients were stable. The mean ± SD change in percent predicted FVC from baseline was 0.2 ± 7.8% at 3 months, -1.3 ± 7.9% at 6 months, and -2.1 ± 9% at 9 months. Diarrhoea was the most common AE experienced by 33% of patients and was generally manageable.CONCLUSION: The results from this real-world clinical setting support findings from previously conducted clinical trials and show that nintedanib is effective for the management of IPF and is associated with disease stabilisation. Nintedanib is generally well tolerated.

respiratory system
Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis

Cameli,P.,Guerrieri,M.,Tommaso,P.,Sirna,P.,Bergantini,L.,D'Alessandro,M.,Elena,B.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5142

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Nintedanib has demonstrated to reduce disease progression and mortality in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF): a reduced dosage is available for tolerability purposes but its clinical effectiveness is yet to be fully clarified. Aims and Objectives: to compare the effectiveness of nintedanib at full and reduced dosage in a cohort of patients with IPF and PPF. Methods: we retrospectively collected the demographic, clinical and respiratory functional data of 345 patients (268 with IPF and 77 with PPF) treated with nintedanib and followed in our Centre from 2015 to 2022. Outcome analysis was focused on all-cause mortality and disease progression expressed as a FVC decline rate > 10%/year. Results: overall, the reduction of dosage was necessary in 132 patients due to safety or tolerability reasons. The outcome analysis showed no differences of mortality and functional decline between patients treated with full or reduced dose of nintedanib (p=0.202 and p=0.564, respectively): a worse survival was observed in patients treated on compassionate grounds due to severe FVC or DLCO reduction at baseline (p=0.0006). Multivariate Cox regression analysis identified male sex (HR 3.48 [1.52-7.95]) a baseline FVC% < 70% (HR 1.25 [1.04-1.38]) and the compassionate treatment regimen (HR 6.4 [2.1-9.6]) as the factors associated with a worse survival. Conclusions: our findings suggest that a reduction of dosage of nintedanib is not associated with worse outcomes and may represent a feasible option for patients unable to tolerate a full-dose treatment regimen.

respiratory system
Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Gioele Castelli,Elisabetta Cocconcelli,Nicol Bernardinello,Elisabetta Balestro,Paolo Spagnolo

DOI: https://doi.org/10.1007/s13665-023-00315-y

2023-06-20

Current Pulmonology Reports

Abstract:AbstractPurpose of ReviewThe approval of nintedanib and pirfenidone has changed the treatment landscape of idiopathic pulmonary fibrosis (IPF); however, both drugs only slow disease progression and are burdened by tolerability issues. We summarize the most advanced developmental drugs in IPF, but also mention selected compounds in earlier phases.Recent FindingsSeveral compounds are currently being tested in IPF; the number of trials has increased exponentially in the last 3 years. Four compounds have reached phase 3: BI101550, an oral PDE4B preferential inhibitor; Pamrevlumab, an anticonnective tissue growth factor intravenous monoclonal antibody; Pentraxin-2, a recombinant human form of serum amyloid protein; Treprostinil, a synthetic prostanoid, with an inhaled formulation, currently used for pulmonary hypertension.SummaryNew drugs are likely to reach the clinic in the near future. This will provide more opportunities for treatment of IPF but will also pose unprecedented challenges regarding drug selection and administration(i.e., sequential vs. combination).
Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Barbara Ruaro,Andrea Salotti,Nicolò Reccardini,Stefano Kette,Beatrice Da Re,Salvatore Nicolosi,Umberto Zuccon,Marco Confalonieri,Lucrezia Mondini,Riccardo Pozzan,Michael Hughes,Paola Confalonieri,Francesco Salton

DOI: https://doi.org/10.3390/ph17010119

IF: 4.6

2024-01-18

Pharmaceuticals

Abstract:Background. Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease with rapidly progressive evolution and an unfavorable outcome. Nintedanib (NTD) is an antifibrotic drug that has been shown to be effective in slowing down the progression of the disease. The aim of our study was to examine the efficacy, especially in terms of the functional decline, and the safety profile of NTD in patients treated with the recommended dose and subjects who reduced or suspended the therapy due to the occurrence of adverse reactions. Methods. We conducted a real-life retrospective study based on the experience of NTD use in two centers between 2015 and 2022. Clinical data were evaluated at baseline, at 6 and 12 months after the NTD introduction in the whole population and in subgroups of patients who continued the full-dose treatment, at a reduced dosage, and at the discontinuation of treatment. The following data were recorded: the demographic features, IPF clinical features, NTD therapeutic dosage, tolerability and adverse events, pulmonary function tests (PFTs), the duration of treatment upon discontinuation, and the causes of interruption. Results. There were 54 IPF patients who were included (29.6% females, with a median (IQR) age at baseline of 75 (69.0–79.0) years). Twelve months after the introduction of the NTD therapy, 20 (37%) patients were still taking the full dose, 11 (20.4%) had reduced it to 200 mg daily, and 15 (27.8%) had stopped treatment. Gastrointestinal intolerance predominantly led to the dose reduction (13.0%) and treatment cessation (20.4%). There were two deaths within the initial 6 months (3.7%) and seven (13.0%) within 12 months. Compared to the baseline, the results of the PFTs remained stable at 6 and 12 months for the entire NTD-treated population, except for a significant decline in the DLCO (% predicted value) at both 6 (38.0 ± 17.8 vs. 43.0 ± 26.0; p = 0.041) and 12 months (41.5 ± 15.3 vs. 44.0 ± 26.8; p = 0.048). The patients who continued treatment at the full dose or a reduced dosage showed no significant differences in the FVC and the DLCO at 12 months. Conversely, those discontinuing the NTD exhibited a statistically significant decline in the FVC (% predicted value) at 12 months compared to the baseline (55.0 ± 13.5 vs. 70.0 ± 23.0; p = 0.035). Conclusions. This study highlights the functional decline of the FVC at 12 months after the NTD initiation among patients discontinuing therapy but not among those reducing their dosage.

pharmacology & pharmacy,chemistry, medicinal
Changes in the expression of alpha(2)-adrenergic receptor subtypes during maturation of neuronal cells from fetal pig superior cervical ganglia.

N. Fraeyman,P. Vanscheeuwijck,J. M. Wang,Y. Huang,W. De Potter,J. Regan

DOI: https://doi.org/10.1016/S0165-3806(99)00078-4

1999-09-06

Abstract:
The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

Chao-Hsien Chen,Hui-Chuan Lin,Ya-Hui Wang,Cheng-Yi Wang,You Shuei Lin,Chih-Cheng Lai

DOI: https://doi.org/10.1371/journal.pone.0251636

IF: 3.7

2021-05-14

PLoS ONE

Abstract:Introduction Nintedanib can inhibit processes involved in the progression of fibrosis and can reduce the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis (IPF) and fibrotic-interstitial lung disease (fibrotic-ILDs). Although the adverse events associated with nintedanib in IPF patients are well known, its safety in other fibrotic-ILD patients remained unclear. Methods We searched PubMed, EMBASE, Cochrane CENTRAL and Cochrane CDSR for randomized controlled studies which compared nintedanib with a placebo in ILD patients. We estimated pooled odds ratios (ORs) and 95% confidence intervals (CIs) for adverse events using the DerSimonian–Laird random-effects model. Results Six studies with a total of 2,583 patients were included in the meta-analysis. The pooled estimates showed that patients treated with nintedanib had a significantly higher likelihood of having any adverse events (OR = 2.39; 95% CI = 1.71–3.36) or adverse events leading to treatment discontinuation (OR = 1.73; 95% CI = 1.34–2.25). However, they had trend to lower likelihood of having fatal adverse events (OR = 0.69; 95% CI = 0.41–1.14) compared with the placebo group. Use of nintedanib was positively associated with diarrhea (OR = 5.96; 95% CI = 4.35–8.16), nausea (OR = 3.00; 95% CI = 1.93–4.66), vomiting (OR = 3.22; 95% CI = 2.17–4.76) and weight loss (OR = 3.38; 95% CI = 1.1.76–6.47). Whereas, patients treated with nintedanib were less likely to have a cough (OR = 0.73; 95% CI = 0.56–0.96) and dyspnea (OR = 0.70; 95% CI = 0.53–0.94). Conclusions Compared to a placebo, nintedanib was associated with a higher risk of adverse events, especially for diarrhea, nausea, vomiting and weight loss, but it was also associated with a lower risk of cough and dyspnea in IPF and fibrotic-ILD patients.

multidisciplinary sciences
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Vinod K Viswanathan,Aloke G Ghoshal,Anant Mohan,Ketaki Patil,Chaitanya Bhargave,Sanjay Choudhari,Suyog Mehta

DOI: https://doi.org/10.1007/s41030-024-00271-1

2024-09-28

Abstract:A severe and progressive interstitial lung disease (ILD) known as idiopathic pulmonary fibrosis (IPF) has an unknown etiology with poorly defined mechanisms of development. Among the currently prescribed pharmacological interventions for IPF, nintedanib demonstrates the ability to decelerate the deterioration of lung function and yield positive clinical outcomes. Multiple randomized placebo-controlled trials have confirmed the efficacy and acceptable safety profile of nintedanib. Real-world evidence studies also support the use of nintedanib in IPF, being an efficient and well-tolerated treatment option. It has the potential to stabilize the disease progression in patients with ILD. Patients with IPF frequently have comorbidities like diabetes and hypertension, which can exacerbate the course of disease, reduce quality of life, and decrease treatment adherence. For well-informed decision-making, it is important for healthcare professionals to recognize the position of nintedanib therapy in IPF with comorbidities. The gastrointestinal adverse effects, notably diarrhea, dominate the nintedanib safety profile. These can be effectively controlled by closely monitoring side effects, administering anti-diarrheal and anti-emetic drugs, reducing the nintedanib dose, and discontinuing it in case of severe symptoms with an option to reintroduce the treatment after side effects subside. Symptomatic interventions and monitoring of liver enzymes may reduce the occurrence of permanent treatment discontinuations.
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

Paolo Cameli,Rosa Metella Refini,Laura Bergantini,Miriana d’Alessandro,Valerio Alonzi,Carlo Magnoni,Paola Rottoli,Piersante Sestini,Elena Bargagli

DOI: https://doi.org/10.3389/fmolb.2020.581828

IF: 6.113

2020-09-04

Frontiers in Molecular Biosciences

Abstract:Background: Pirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease. Here, we describe our almost 10 years real-life experience with antifibrotic treatment to investigate potential differences in terms of efficacy.Population and Methods: We retrospectively recruited patients diagnosed with IPF and treated with pirfenidone or nintedanib at Siena Referral Center. Clinical, functional, safety and radiological data was collected at baseline and during the follow-up, according to our Center protocol.Results: We retrospectively recruited 263 IPF patients (139 treated with pirfenidone and 124 with nintedanib) in the study. After 885.3 ± 559.5 days of observation, the median survival was 1224 days. No significant differences were found between pirfenidone and nintedanib in terms of survival and time to decline of forced vital capacity >10% (p = 0.8786 and p = 0.1677, respectively). A smaller lung diffusion for carbon monoxide (DLCO) decrease was found after 1 year of therapy with nintedanib in respect to pirfenidone (p = 0.0167). Overall, 21 patients permanently discontinued antifibrotic treatment due to side effects (14 with pirfenidone, 7 with nintedanib); no fatal adverse events were recorded.Discussion: Our results showed a similar effectiveness between pirfenidone and nintedanib in terms of mortality and functional disease progression. Both drugs confirmed their good tolerability profile and no new safety alerts were observed. Nintedanib was associated with a smaller reduction of DLCO after 1 year of follow-up compared with pirfenidone, maybe due to its antiangiogenic properties.

biochemistry & molecular biology
Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

Pilar Rivera-Ortega,Conal Hayton,John Blaikley,Colm Leonard,Nazia Chaudhuri

DOI: https://doi.org/10.1177/1753466618800618

2018-01-01

Therapeutic Advances in Respiratory Disease

Abstract:Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease associated with significant morbidity and mortality. Previously, IPF has been managed using immunosuppressive therapy; however, it has been shown that this is associated with increased mortality. In the last 5 years, two disease-modifying agents have been licensed for use in IPF, namely pirfenidone and nintedanib. Nintedanib is a tyrosine kinase inhibitor with antifibrotic properties that has also been shown to significantly reduce the progression of the disease. The scientific evidence shows that nintedanib is effective and well tolerated for the treatment of IPF in mild, moderate and severe stages of the disease. Real-world experiences also support the findings of previously conducted clinical trials and show that nintedanib is effective for the management of IPF and is associated with reducing disease progression. Gastrointestinal events, mainly diarrhoea, are the main adverse events caused by the treatment. Recent real-word studies also suggest that nintedanib stabilizes lung function till lung transplantation, with no increased surgical complications or postoperative mortality after lung transplantation. In this review, we will discuss the clinical trial evidence and real-world experience for nintedanib in the management of IPF.

respiratory system
Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

Stefano Levra,Giuseppe Guida,Andrea Elio Sprio,Flavio Crosa,Paolo Carlo Ghio,Francesca Bertolini,Vitina Carriero,Carlo Albera,Fabio Luigi Massimo Ricciardolo

DOI: https://doi.org/10.3390/biomedicines10123229

IF: 4.757

2022-12-12

Biomedicines

Abstract:Pirfenidone and nintedanib are the only two drugs approved for the treatment of idiopathic pulmonary fibrosis (IPF). Both proved to be safe and well-tolerated in clinical trials, but real-world data and direct comparisons are scarce. This real-life study explored the safety profile of pirfenidone and nintedanib with a prolonged follow-up. We retrospectively collected clinical status, adverse events (AEs), and treatment changes from IPF patients who had started an antifibrotic treatment at our centre from December 2011 to December 2020, including 192 patients treated with pirfenidone and 89 with nintedanib. The majority of patients in both groups experienced one or more AEs during the follow-up. A higher proportion of AEs in the nintedanib group were effectively treated with behavioural modifications or additional medications compared with the pirfenidone group (52.5% vs. 40.6%, p = 0.04). Overall, a difference in the impact of AEs due to nintedanib versus pirfenidone resulted in a lower permanent discontinuation of therapy (8.3% vs. 18.3%, p = 0.02), with the latter being associated with a higher risk of drug discontinuation at 48 months after initiation (OR = 2.52, p = 0.03). Our study confirms the safety profile of antifibrotic drugs in IPF but highlights that AEs due to nintedanib are usually easier to manage and lead to fewer cases of permanent discontinuation of therapy.
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting

Gabriela Santos,André Fabiano,Patrícia Caetano Mota,Inês Rodrigues,Diogo Carvalho,Natália Melo,Hélder Novais-Bastos,André Terras Alexandre,Conceição Souto Moura,Susana Guimarães,José Miguel Pereira,André Carvalho,António Morais

DOI: https://doi.org/10.1016/j.pupt.2023.102261

Abstract:Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that is associated with radiological and/or histological features of usual interstitial pneumonia (UIP). A mean survival of 2-5 years was reported previously to the advent of antifibrotics. According to clinical trials, nintedanib and pirfenidone induce a significant delay in functional decline, with a favorable impact on survival. Methods: A real-life retrospective and longitudinal study was conducted to assess the efficacy and tolerability of antifibrotics in IPF patients, between January 2014 and December 2020. Two groups (under nintedanib or pirfenidone) were analyzed at diagnosis through their clinical features and radiological patterns. Lung function was assessed at diagnosis (time 0) and after 6, 12 and 24 months of treatment. We also compared this antifibrotic cohort with an older naïve antifibrotic cohort, mainly treated with immunosuppressive drugs and/or N- acetylcysteine. Survival was analyzed and prognostic features were also studied. Statistical analysis was performed with IBM® SPSS®. Results: A cohort of 108 patients under antifibrotics (nintedanib n = 54; pirfenidone n = 54) was assessed. Lung function analysis showed an overall stabilization in FVC and DLCO mean predicted percentages at 6, 12 and 24 months of treatment. The mean decline in FVC and DLCO, at 12 months, was -40.95 ± 438.26 mL and -0.626 ± 1.31 mL/min/mmHg, respectively. However, during this period, 34.2% of the patients died mostly due to acute exacerbation associated with a poorer lung function at diagnosis. Mean survival in the naïve antifibrotic cohort was significantly lower than in the antifibrotic cohort (39.9 months versus 58.2 months; p < 0.005). Regarding lung function evolution and survival, we found no differences between definitive or probable UIP radiological patterns, both on patients under nintedanib and pirfenidone (p = 0.656). Conclusions: In this real-life observational study, the positive impact of antifibrotic therapy on the IPF clinical course and on survival was corroborated. Regarding efficacy, there was no difference between patients taking nintedanib or pirfenidone. The need for an early treatment was also demonstrated, since a worse outcome is clearly associated with lower lung volumes and lower diffusing capacity at diagnosis.
Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Ioannis A Dimitroulis,I. A. Dimitroulis

DOI: https://doi.org/10.4187/respcare.03023

2014-04-29

Respiratory Care

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrotic lung disease with no clear etiology and few therapeutic options. Growth factors that act as mediators in the development of this disease might be important therapeutic targets. Nintedanib is a triple-tyrosine kinase inhibitor and a potent antagonist of growth factors such as platelet-derived growth factor, vascular endothelial growth factor, and basic fibroblast growth factor, and it is currently evaluated in clinical trials as a potential IPF therapy. Treatment with nintedanib may slow decline in lung function, decrease the frequency of exacerbations, and improve quality of life in subjects with IPF. This observation, together with extensive safety and pharmacokinetic data from studies of nintedanib in malignancy, led the way for the clinical development of this drug in IPF. Observations from clinical trials, together with the preclinical data, suggest that nintedanib may become an important therapeutic option for individuals with IPF. High-dose nintedanib improved the quality of life, slowed the progression of lung fibrosis and the decline of lung function, and reduced the rate of exacerbations in individuals with mild and moderate IPF. This is a short review based on the available data (September 2013) on nintedanib.

respiratory system,critical care medicine
Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Anna J Podolanczuk,Kerri I Aronson,Podolanczuk,A. J.,Aronson,K. I.

DOI: https://doi.org/10.1183/13993003.00067-2024

2024-02-01

ERS Monograph

Abstract:Extract Patients diagnosed with pulmonary fibrosis face progressive loss of lung function and debilitating symptoms such as shortness of breath, cough and fatigue. Historically, clinical trials of novel therapies for pulmonary fibrosis have focused on slowing disease progression, as defined by a decline in forced vital capacity (FVC). Landmark studies such as ASCEND, CAPACITY and INPULSIS paved the way for approval of the first anti-fibrotic drugs for idiopathic pulmonary fibrosis (IPF) by establishing their ability to slow FVC decline [1–3]. The INBUILD clinical trial extended the indication for anti-fibrotic treatment to a broader group of fibrotic lung diseases by showing that nintedanib slows FVC decline in those with other forms of progressive pulmonary fibrosis (PPF) [4]. However, both nintedanib and pirfenidone fell short in demonstrating an impact on symptoms and quality of life, leaving these crucial components of the patient experience unaddressed.
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy

Claudia Landi,Laura Bergantini,Paolo Cameli,Miriana d'Alessandro,Alfonso Carleo,Enxhi Shaba,Paola Rottoli,Luca Bini,Elena Bargagli

DOI: https://doi.org/10.1038/s41598-020-66296-z

2020-06-10

Abstract:Idiopathic pulmonary fibrosis (IPF) is a fatal progressive disease with a median survival of 2-5 years. Nintedanib is a small tyrosine kinase inhibitor that reduces IPF progression, significantly slowing the annual decline in Forced Vital Capacity (FVC). Very little data is available on the molecular mechanisms of this treatment in IPF, despite a growing interest in the definition of IPF pathogenesis and target therapy. A functional proteomic approach was applied to the analysis of serum samples from IPF patients in order to highlight differential proteins potentially indicative of drug-induced molecular pathways modifications and response to therapy. Twelve serum samples were collected from six IPF patients in care at Siena Regional Referral Center for Interstitial Lung Diseases (ILDs) and treated with nintedanib for one year. Serum samples were analyzed at baseline (T0 before starting therapy) and after one year of treatment (T1) and underwent differential proteomic and bioinformatic analysis. Proteomic analysis revealed 13 protein species that were significantly increased after one year of treatment. When the targets of nintedanib (VEGFR, FGFR and PDGFR) were added, enrichment analysis extracted molecular pathways and process networks involved in cell differentiation (haptoglobin and albumin), coagulation (antithrombin III), epithelial mesenchymal transition, cell proliferation and transmigration. PI3K and MAPK induced up-regulation of apolipoprotein C3. Proteomic study found 13 protein species up-regulated in IPF patients after one year of nintedanib treatment. Haptoglobin, a central hub of our analysis was validated by 2D-WB and ELISA as theranostic marker in a more numerous populations of patients.
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Yvette N Lamb

DOI: https://doi.org/10.1007/s40265-021-01487-0

Drugs

Abstract:Progressive fibrosing interstitial lung diseases (ILDs) involve similar pathophysiological processes, indicating the potential for common approaches to treatment. Nintedanib (Ofev®), an intracellular tyrosine kinase inhibitor (TKI) with antifibrotic properties, was one of the first drugs approved for use in idiopathic pulmonary fibrosis (IPF) and has more recently been approved for use in other chronic fibrosing ILDs with a progressive phenotype and systemic sclerosis-associated ILD (SSc-ILD). In multinational phase III trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) in adults with IPF, other progressive fibrosing ILDs and SSc-ILD. Reductions in FVC decline with nintedanib in patients with IPF and severe gas exchange impairment were comparable to those in patients with milder disease. Real-world experience in patients with IPF supports the effectiveness of nintedanib in slowing ILD progression. Nintedanib had a manageable tolerability profile in patients with fibrotic ILDs in clinical trials and real-world studies. No new safety signals have emerged from global pharmacovigilance data. Nintedanib continues to represent an important therapeutic option in patients with IPF and is the first drug to be approved for use in patients with other chronic fibrosing ILDs with a progressive phenotype or SSc-ILD, with these approvals expanding the range of fibrotic ILDs for which nintedanib can be prescribed.
Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Nazia Chaudhuri,Arata Azuma,Kamila Sroka-Saidi,Elvira Erhardt,Ivana Ritter,Sergio Harari

DOI: https://doi.org/10.1007/s12325-024-03023-4

2024-11-11

Advances in Therapy

Abstract:Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF), other forms of progressive pulmonary fibrosis (PPF), and systemic sclerosis-associated interstitial lung disease (ILD). We present global post-marketing safety data for nintedanib in these fibrosing ILDs.

pharmacology & pharmacy,medicine, research & experimental
Subgroup Analysis for Chinese Patients Included in the INPULSIS ® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis

Zuojun Xu,Huiping Li,Fuqiang Wen,Chunxue Bai,Ping Chen,Feng Fan,Na Hu,Susanne Stowasser,Jian Kang

DOI: https://doi.org/10.1007/s12325-019-0887-1

2019-01-01

Advances in Therapy

Abstract:Purpose To investigate the efficacy and safety of nintedanib versus placebo in Chinese patients with idiopathic pulmonary fibrosis (IPF). Methods The INPULSIS ® trials consisted of two replicate, randomized, placebo-controlled, double-blind trials comparing nintedanib 150 mg bid with placebo over a 52-week treatment period. The primary endpoint was annual rate of decline in forced vital capacity (FVC); key secondary endpoints were change from baseline in Saint George’s Respiratory Questionnaire’s total score and time to first investigator-reported acute exacerbation. Data from both trials were pooled for the Chinese subgroup analyses. Results A total of 101 Chinese patients (nintedanib/placebo: 61/40) were treated. The demographic characteristics were generally balanced between treatment arms. Over 52 weeks, the rate of decline in FVC was lower in nintedanib-treated patients compared with placebo-treated patients in the Chinese subgroup [− 126.43 vs. − 229.82 mL/year; ∆ = 103.39 mL/year (95% confidence interval, CI: − 19.40 to 226.18)]. The proportion of patients with adverse events (AEs) over 52 weeks was similar between treatment arms. The most commonly reported AEs with nintedanib treatment were gastrointestinal symptoms (diarrhoea, nausea, and vomiting). Conclusions Nintedanib is clinically efficacious in Chinese patients with IPF with approximately 50% reductions in the rate of decline in FVC, demonstrating slowed disease progression. Similar to the overall INPULSIS ® population, nintedanib has a favourable benefit/risk profile in Chinese patients with IPF. ClinicalTrials.gov identifiers NCT01335464, NCT01335477. Funding Boehringer Ingelheim. Plain Language Summary Plain language summary available for this article.

Enteric fever in an under 5-year-old.

Real-world Experience of Nintedanib Therapy in Idiopathic-inflammatory-myopathy-related Interstitial Lung Disease: Efficacy and Tolerability

The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis

Succinic thiokinase. IV. Improved method of purification, arsenolysis of guanosine triphosphate, succinate-dependent guanosine triphos- phatase activity, and some other properties of the enzyme.

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Comparison of the clinical effectiveness of nintedanib at full and reduced dosage in patients with idiopathic pulmonary fibrosis and progressive non-idiopathic fibrosis

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study

Changes in the expression of alpha(2)-adrenergic receptor subtypes during maturation of neuronal cells from fetal pig superior cervical ganglia.

The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience

The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting

Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Nintedanib and symptoms of fibrotic lung disease: a glimmer of hope for patients living with pulmonary fibrosis

Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy

Nintedanib: A Review in Fibrotic Interstitial Lung Diseases

Safety and Tolerability of Nintedanib in Patients with Fibrosing Interstitial Lung Diseases: Post-marketing Data

Subgroup Analysis for Chinese Patients Included in the INPULSIS ® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis